A Biotech Investment Option for Cautious Investors in a Volatile Sector
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 09 2025
0mins
Should l Buy LGND?
Source: CNBC
Investment Recommendation: Citigroup has initiated a buy rating for Ligand Pharmaceuticals with a price target of $270, suggesting a potential upside of 46% from its current price of $184.67, as the stock has already risen nearly 79% this year.
Stock Valuation Insights: Analyst Yigal Nochomovitz believes that Ligand's current stock price does not fully reflect its potential value, citing upcoming catalysts from partnered programs that could drive further growth.
Risk Mitigation Strategy: Ligand is positioned as a conservative investment in the biotech sector, with a diversified portfolio that reduces volatility compared to other biotech firms that often focus on one or two drugs.
Revenue Projections: The company is expected to see increased royalty revenue from its products, with significant contributions anticipated from Filspari and Ohtuvayre, which are projected to generate over $1 billion in sales by 2027.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LGND?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LGND
Wall Street analysts forecast LGND stock price to rise
6 Analyst Rating
6 Buy
0 Hold
0 Sell
Strong Buy
Current: 208.160
Low
220.00
Averages
237.20
High
270.00
Current: 208.160
Low
220.00
Averages
237.20
High
270.00
About LGND
Ligand Pharmaceuticals Incorporated is a biopharmaceutical company enabling scientific advancement through supporting the clinical development of medicines. It does this by financing, licensing its technologies or both. It operates two infrastructure-light royalty-generating IP platform technologies. Its Captisol platform technology is a chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. This technology has enabled FDA-approved products, including Gilead’s Veklury, Amgen’s Kyprolis, Baxter’s Nexterone, and Acrotech Biopharma’s Evomela. Its NITRICIL platform technology facilitates tunable dosing, permitting an adjustable drug release profile to allow proprietary formulations that target a range of indications. Its technologies also include HepDirect, LTP and BEPro Technology Platform, and Pelican Expression Technology. It has multiple alliances, licenses and other business relationships with various pharmaceutical companies.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Rice Hall James Increases Stake in QuidelOrtho
- Share Increase: Rice Hall James & Associates acquired 574,877 shares of QuidelOrtho in Q4 2026, reflecting confidence in the company's future prospects despite a 43.4% decline in stock price over the past year.
- Investment Value: This acquisition raised QuidelOrtho's stake to 1.3% of the fund's 13F reportable assets, indicating recognition of its potential value, which may attract further investor interest.
- Market Performance: As of February 13, 2026, QuidelOrtho's market capitalization stood at $1.6 billion with a current price of $23.58, trailing the S&P 500 by 55.2 percentage points, highlighting competitive pressures in the market.
- Strategic Adjustments: QuidelOrtho is undergoing strategic adjustments, including strengthening its product pipeline and improving spending returns, with analysts expecting these efforts to yield modest revenue and operating profit growth in the coming years.
See More
Rice Hall James Increases Stake in QuidelOrtho
- Increased Holdings: Rice Hall James purchased 574,877 shares of QuidelOrtho in Q4, raising its total stake to 833,791 shares valued at $23.8 million, reflecting a positive outlook on the company's future prospects.
- Investment Value Growth: The position's value increased by $16.2 million at quarter-end, indicating a rise in stock price and additional share purchases, suggesting the fund's optimistic view on QuidelOrtho's potential value.
- Industry Position: As a leader in in vitro diagnostics, QuidelOrtho has struggled with consistent revenue growth and profitability in recent years, but its strategic adjustments and strengthened product pipeline may improve financial performance, attracting value investors.
- Market Expectations: Analysts expect QuidelOrtho to achieve modest revenue and operating profit growth in the coming years, although the Motley Fool analyst team did not include it in their list of top investment stocks, indicating a divergence in market perceptions of its potential.
See More
Rice Hall James Increases Stake in Stride by 122,430 Shares
- Share Increase: Rice Hall James & Associates, LLC increased its stake in Stride by 122,430 shares in Q4 2026, bringing its ownership to 1.5%, indicating confidence in Stride's future growth potential.
- Market Value Fluctuation: Despite the increase, Stride's quarter-end market value fell by $17.7 million, reflecting the impact of stock price movements and additional shares, suggesting market concerns about its short-term performance.
- Earnings Outlook: During Stride's Q4 earnings call, management reaffirmed full-year revenue guidance while raising adjusted operating income expectations, indicating that the market's negative reaction may have been overstated, presenting a potential undervaluation opportunity.
- Market Performance: Stride's stock price has dropped 39.5% over the past year and underperformed the S&P 500 by 51.2 percentage points, highlighting challenges in the education market but also providing potential buying opportunities for investors.
See More
Ligand Pharmaceuticals Reports Strong Q4 2025 Earnings and Growth Outlook
- Exceptional Financial Performance: Ligand Pharmaceuticals exceeded its original 2025 adjusted EPS guidance by over 30%, reporting total revenue of $268 million, a 60% increase year-over-year, showcasing the company's strong market performance and enhanced profitability.
- Royalty Revenue Growth: Royalty revenue reached $161 million in 2025, up 48% year-over-year, primarily driven by successful launches of FILSPARI, Ohtuvayre, and CAPVAXIVE, indicating effective strategies in new product development and market penetration.
- Optimistic Future Outlook: Management expects adjusted EPS for 2026 to be between $8 and $9, with royalty revenue projected to grow by 32%, reflecting confidence in future revenue growth and a strategic focus on continued investment in new products.
- Portfolio Management Upgrade: The company has launched a more systematic portfolio management process aimed at actively driving value across partnerships, further enhancing its competitive position and market standing in the biopharmaceutical sector.
See More
Ligand Pharmaceuticals Reports Strong 2025 Financial Performance with 48% Royalty Revenue Growth
- Financial Performance Growth: Ligand Pharmaceuticals reported total revenues of $268.1 million for 2025, a 60% increase from $167.1 million in 2024, with royalty revenue rising 45% to $161.0 million, showcasing the company's success in investing in high-value assets.
- Strong Fourth Quarter Results: In Q4 2025, revenues reached $59.7 million, up 39% from $42.8 million in Q4 2024, primarily driven by increased sales of products from Travere Therapeutics and Merck, further solidifying Ligand's market position.
- Adjusted Net Income Surge: The adjusted net income for Q4 2025 was $42.7 million, or $2.02 per diluted share, significantly up from $25.2 million and $1.27 per diluted share in Q4 2024, reflecting robust performance in royalty revenue growth.
- 2026 Financial Guidance Reaffirmed: Ligand expects total revenues for 2026 to range between $245 million and $285 million, with adjusted earnings per diluted share projected at $8.00 to $9.00, demonstrating confidence in future growth and the sustainability of its strategic planning.
See More
Ligand Pharmaceuticals Releases 2026 Financial Guidance
- Earnings Beat: Ligand Pharmaceuticals reported a Q4 non-GAAP EPS of $2.02, exceeding expectations by $0.52, indicating strong profitability that is likely to positively impact stock performance.
- Significant Revenue Growth: The company achieved Q4 revenue of $59.7 million, a 39.5% year-over-year increase, surpassing market expectations by $4.11 million, demonstrating robust demand and sales that bolster investor confidence.
- 2026 Financial Guidance Reaffirmed: Ligand reaffirmed its 2026 financial guidance, projecting adjusted earnings per diluted share between $8.00 and $9.00, reflecting confidence in future profitability that may attract more investor interest.
- Diverse Revenue Streams: The company anticipates 2026 royalty revenue between $200 million and $225 million, Captisol sales between $35 million and $40 million, and contract revenue between $10 million and $20 million, leading to total revenue expectations of $245 million to $285 million, showcasing a diverse and stable revenue structure.
See More
Rice Hall James Increases Stake in QuidelOrtho
- Share Increase: Rice Hall James & Associates acquired 574,877 shares of QuidelOrtho in Q4 2026, reflecting confidence in the company's future prospects despite a 43.4% decline in stock price over the past year.
- Investment Value: This acquisition raised QuidelOrtho's stake to 1.3% of the fund's 13F reportable assets, indicating recognition of its potential value, which may attract further investor interest.
- Market Performance: As of February 13, 2026, QuidelOrtho's market capitalization stood at $1.6 billion with a current price of $23.58, trailing the S&P 500 by 55.2 percentage points, highlighting competitive pressures in the market.
- Strategic Adjustments: QuidelOrtho is undergoing strategic adjustments, including strengthening its product pipeline and improving spending returns, with analysts expecting these efforts to yield modest revenue and operating profit growth in the coming years.
See More
Rice Hall James Increases Stake in QuidelOrtho
- Increased Holdings: Rice Hall James purchased 574,877 shares of QuidelOrtho in Q4, raising its total stake to 833,791 shares valued at $23.8 million, reflecting a positive outlook on the company's future prospects.
- Investment Value Growth: The position's value increased by $16.2 million at quarter-end, indicating a rise in stock price and additional share purchases, suggesting the fund's optimistic view on QuidelOrtho's potential value.
- Industry Position: As a leader in in vitro diagnostics, QuidelOrtho has struggled with consistent revenue growth and profitability in recent years, but its strategic adjustments and strengthened product pipeline may improve financial performance, attracting value investors.
- Market Expectations: Analysts expect QuidelOrtho to achieve modest revenue and operating profit growth in the coming years, although the Motley Fool analyst team did not include it in their list of top investment stocks, indicating a divergence in market perceptions of its potential.
See More
Rice Hall James Increases Stake in Stride by 122,430 Shares
- Share Increase: Rice Hall James & Associates, LLC increased its stake in Stride by 122,430 shares in Q4 2026, bringing its ownership to 1.5%, indicating confidence in Stride's future growth potential.
- Market Value Fluctuation: Despite the increase, Stride's quarter-end market value fell by $17.7 million, reflecting the impact of stock price movements and additional shares, suggesting market concerns about its short-term performance.
- Earnings Outlook: During Stride's Q4 earnings call, management reaffirmed full-year revenue guidance while raising adjusted operating income expectations, indicating that the market's negative reaction may have been overstated, presenting a potential undervaluation opportunity.
- Market Performance: Stride's stock price has dropped 39.5% over the past year and underperformed the S&P 500 by 51.2 percentage points, highlighting challenges in the education market but also providing potential buying opportunities for investors.
See More
Ligand Pharmaceuticals Reports Strong Q4 2025 Earnings and Growth Outlook
- Exceptional Financial Performance: Ligand Pharmaceuticals exceeded its original 2025 adjusted EPS guidance by over 30%, reporting total revenue of $268 million, a 60% increase year-over-year, showcasing the company's strong market performance and enhanced profitability.
- Royalty Revenue Growth: Royalty revenue reached $161 million in 2025, up 48% year-over-year, primarily driven by successful launches of FILSPARI, Ohtuvayre, and CAPVAXIVE, indicating effective strategies in new product development and market penetration.
- Optimistic Future Outlook: Management expects adjusted EPS for 2026 to be between $8 and $9, with royalty revenue projected to grow by 32%, reflecting confidence in future revenue growth and a strategic focus on continued investment in new products.
- Portfolio Management Upgrade: The company has launched a more systematic portfolio management process aimed at actively driving value across partnerships, further enhancing its competitive position and market standing in the biopharmaceutical sector.
See More
Ligand Pharmaceuticals Reports Strong 2025 Financial Performance with 48% Royalty Revenue Growth
- Financial Performance Growth: Ligand Pharmaceuticals reported total revenues of $268.1 million for 2025, a 60% increase from $167.1 million in 2024, with royalty revenue rising 45% to $161.0 million, showcasing the company's success in investing in high-value assets.
- Strong Fourth Quarter Results: In Q4 2025, revenues reached $59.7 million, up 39% from $42.8 million in Q4 2024, primarily driven by increased sales of products from Travere Therapeutics and Merck, further solidifying Ligand's market position.
- Adjusted Net Income Surge: The adjusted net income for Q4 2025 was $42.7 million, or $2.02 per diluted share, significantly up from $25.2 million and $1.27 per diluted share in Q4 2024, reflecting robust performance in royalty revenue growth.
- 2026 Financial Guidance Reaffirmed: Ligand expects total revenues for 2026 to range between $245 million and $285 million, with adjusted earnings per diluted share projected at $8.00 to $9.00, demonstrating confidence in future growth and the sustainability of its strategic planning.
See More
Ligand Pharmaceuticals Releases 2026 Financial Guidance
- Earnings Beat: Ligand Pharmaceuticals reported a Q4 non-GAAP EPS of $2.02, exceeding expectations by $0.52, indicating strong profitability that is likely to positively impact stock performance.
- Significant Revenue Growth: The company achieved Q4 revenue of $59.7 million, a 39.5% year-over-year increase, surpassing market expectations by $4.11 million, demonstrating robust demand and sales that bolster investor confidence.
- 2026 Financial Guidance Reaffirmed: Ligand reaffirmed its 2026 financial guidance, projecting adjusted earnings per diluted share between $8.00 and $9.00, reflecting confidence in future profitability that may attract more investor interest.
- Diverse Revenue Streams: The company anticipates 2026 royalty revenue between $200 million and $225 million, Captisol sales between $35 million and $40 million, and contract revenue between $10 million and $20 million, leading to total revenue expectations of $245 million to $285 million, showcasing a diverse and stable revenue structure.
See More
